Superparamagnetic iron oxide nanoparticles for in vivo molecular and cellular imaging

Contrast Media and Molecular Imaging

Volumn 10, Issue 5, 2015, Pages 329-355

  Sharifi, Shahriar ^a   Seyednejad, Hajar ^b   Laurent, Sophie ^c,d   Atyabi, Fatemeh ^e   Saei, Amir Ata ^e,f   Mahmoudi, Morteza ^e,g  

^a UNIVERSITY OF TWENTE   (Netherlands)

^b Rice University   (United States)

^c UNIVERSITY OF MONS   (Belgium)

^d Center for Microscopy and Molecular Imaging (CMMI)   (Belgium)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f KAROLINSKA INSTITUTE   (Sweden)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cellular imaging; Iron oxide; Molecular imaging; MRI; SPIONs; Superparamagnetic nanoparticles

Indexed keywords

SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; FERRIC ION; FERRIC OXIDE; METAL NANOPARTICLE;

ARTHRITIS; CARDIOVASCULAR DISEASE; CELL LABELING; CELL MIGRATION; CELL TRACKING; CELL VIABILITY; CENTRAL NERVOUS SYSTEM DISEASE; CHONDROGENESIS; CONTRAST ENHANCEMENT; DEGENERATIVE DISEASE; DIAGNOSTIC IMAGING; DRUG UPTAKE; GASTROINTESTINAL TRACT; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; INFECTION; INFLAMMATION; INTERVERTEBRAL DISK; LIVER DISEASE; LYMPH NODE; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; SPINAL CORD REGENERATION; STEM CELL; TISSUE ENGINEERING; CHEMISTRY; PROCEDURES;

FERRIC COMPOUNDS; HUMANS; MAGNETIC RESONANCE IMAGING; METAL NANOPARTICLES;

EID: 84943582958     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.1638     Document Type: Review

References (364)

1. Weissleder R, Ross BD, Rehemtulla A, Gambhir SS. Molecular Imaging: Principles and Practice. People's Medical Publishing House: Shelton, CT, USA, 2010.
2. Nolting DD, Gore JC, Pham W. Near-infrared dyes: probe development and applications in optical molecular imaging. Curr Org Synth 2011; 8(4): 521-534.
3. Modo MMJ, Bulte JWM. Molecular and Cellular MR Imaging. CRC Press: Boca Raton, FL, 2007.
4. Mahmoudi M, Serpooshan V, Laurent S. Engineered nanoparticles for biomolecular imaging. Nanoscale 2011; 3(8): 3007-3026.
5. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 2003; 17(5): 545-580.
6. Debbage P, Jaschke W. Molecular imaging with nanoparticles: giant roles for dwarf actors. Histochem Cell Biol 2008; 130(5): 845-875.
7. Kiessling F, Liu Z, Gätjens J. Advanced nanomaterials in multimodal imaging: design, functionalization, and biomedical applications. J Nanomater 2010; 2010: 894303.
8. Rinck P. Magnetic Resonance in Medicine (4th ed). Wiley-Blackwell: Minusio, Switzerland, 2001.
9. Mahmoudi M, Stroeve P, Milani AS, Arbab SA. Superparamagnetic Iron Oxide Nanoparticles: Synthesis, Surface Engineering, Cytotoxicity and Biomedical Applications. Nova Science Publisher: New York, 2010, ISBN: 978-1-61668-964-3.
10. Vande Velde G, Baekelandt V, Dresselaers T, Himmelreich U. Magnetic resonance imaging and spectroscopy methods for molecular imaging. Q J Nucl Med Mol Imaging 2009; 53(6): 565-585.
11. Laurent S, Forge D, Port M, Roch A, Robic C, Vander Elst L, Muller RN. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations and biological applications. Chem Rev 2008; 108(6): 2064-2110.
12. Mahmoudi M, Sant S, Wang B, Laurent S, Sen T. Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy. Adv Drug Deliv Rev 2011; 63(1/2): 24-46.
13. Sharifi S, Behzadi S, Laurent S, Forrest ML, Stroeve P, Mahmoudi M. Toxicity of nanomaterials. Chem Soc Rev 2012; 41: 2323-2343.
14. Mahmoudi M, Hosseinkhani H, Hosseinkhani M, Boutry S, Simchi A, Journeay WS, Subramani K, Laurent S. Magnetic resonance imaging tracking of stem cells in vivo using iron oxide nanoparticles as a tool for the advancement of clinical regenerative medicine. Chem Rev 2011; 111(2): 253-280.
15. Mahmoudi M, Hofmann H, Rothen-Rutishauser B, Petri-Fink A. Assessing the in vitro and in vivo toxicity of superparamagnetic iron oxide nanoparticles. Chem Rev 2011; 112(4): 2323-2338.
16. Mahmoudi M, Laurent S, Shokrgozar MA, Hosseinkhani M. Toxicity evaluations of superparamagnetic iron oxide nanoparticles: cell 'vision' versus physicochemical properties of nanoparticles. ACS Nano 2011; 5(9): 7263-7276.
17. Mahmoudi M, Simchi A, Imani M. Cytotoxicity of uncoated and polyvinyl alcohol coated superparamagnetic iron oxide nanoparticles. J Phys Chem C 2009; 113(22): 9573-9580.
18. Amiri H, Mahmoudi M, Lascialfari A. Superparamagnetic colloidal nanocrystal clusters coated with polyethylene glycol fumarate: a possible novel theranostic agent. Nanoscale 2011; 3: 1022-1030.
19. Rauch J, Kolch W, Mahmoudi M. Cell type-specific activation of AKT and ERK signaling pathways by small negatively-charged magnetic nanoparticles. Sci Rep 2012; 2: 868.
20. Laurent S, Duts S, Hafeli U, Mahmoudi M. Magnetic fluid hyperthermia: focus on superparamagnetic iron oxide nanoparticles. Adv Colloid Interface Sci 2011; 166: 8-23.
21. Laurent S, Mahmoudi M. Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of cancer. Int J Mol Epidemiol Genet 2011; 2(4): 367.
22. Mahmoudi M, Sahraian MA, Shokrgozar MA, Laurent S. Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of multiple sclerosis. ACS Chem Neurosci 2011; 2(3): 118-140.
23. Hajipour MJ, Fromm KM, AkbarAshkarran A, Jimenez de Aberasturi D, Larramendi IRd, Rojo T, Serpooshan V, Parak WJ, Mahmoudi M. Antibacterial properties of nanoparticles. Trends Biotechnol 2012; 30(10): 499-511.
24. Laurent S, Saei AA, Behzadi S, Panahifar A, Mahmoudi M. Superparamagnetic iron oxide nanoparticles for delivery of therapeutic agents: opportunities and challenges. Expert Opin Drug Deliv 2014; 11(9): 1449-1470.
25. Corot C, Robert P, Idée JM, Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev 2006; 58(14): 1471-1504.
26. Laurent S, Bridot J-L, Elst LV, Muller RN. Magnetic iron oxide nanoparticles for biomedical applications. Future Med Chem 2010; 2(3): 427-449.
27. Mahmoudi M, Simchi A, Milani A, Stroeve P. Cell toxicity of superparamagnetic iron oxide nanoparticles. J Colloid Interface Sci 2009; 336(2): 510-518.
28. Lee N, Hyeon T. Designed synthesis of uniformly sized iron oxide nanoparticles for efficient magnetic resonance imaging contrast agents. Chem Soc Rev 2012; 41(7): 2575-2589.
29. Mornet S, Vasseur S, Grasset F, Duguet E. Magnetic nanoparticle design for medical diagnosis and therapy. J Mater Chem 2004; 14(14): 2161-2175.
30. Berry CC, Wells S, Charles S, Curtis ASG. Dextran and albumin derivatised iron oxide nanoparticles: influence on fibroblasts in vitro. Biomaterials 2003; 24(25): 4551-4557.
31. Lee K, Kim S-G, Kim W-S, Kim S. Properties of iron oxide particles prepared in the presence of dextran. Korean J Chem Eng 2002; 19(3): 480-485.
32. Laurent S, Nicotra C, Gossuin Y, Roch A, Ouakssim A, Vander Elst L, Cornant M, Soleil P, Muller RN. Influence of the length of the coating molecules on the nuclear magnetic relaxivity of superparamagnetic colloids. Phys Status Solididi C 2004; 1(12): 3644-3650.
33. Gamarra LF, Brito GES, Pontuschka WM, Amaro E, Parma AHC, Goya GF. Biocompatible superparamagnetic iron oxide nanoparticles used for contrast agents: a structural and magnetic study. J Magn Magn Mater 2005; 289: 439-441.
34. Paul KG, Frigo TB, Groman JY, Groman EV. Synthesis of ultrasmall superparamagnetic iron oxides using reduced polysaccharides. Bioconjugate Chem 2004; 15(2): 394-401.
35. Carmen Bautista M, Bomati-Miguel O, Del Puerto MM, Serna CJ, Veintemillas-Verdaguer S. Surface characterisation of dextran-coated iron oxide nanoparticles prepared by laser pyrolysis and coprecipitation. J Magn Magn Mater 2005; 293(1): 20-27.
36. Nishio Y, Yamada A, Ezaki K, Miyashita Y, Furukawa H, Horie K. Preparation and magnetometric characterization of iron oxide-containing alginate/poly(vinyl alcohol) networks. Polymer 2004; 45(21): 7129-7136.
37. Finotelli PV, Morales MA, Rocha-Leão MH, Baggio-Saitovitch EM, Rossi AM. Magnetic studies of iron(III) nanoparticles in alginate polymer for drug delivery applications. Mater Sci Eng C 2004; 24(5): 625-629.
38. Ma H-L, Qi X-R, Maitani Y, Nagai T. Preparation and characterization of superparamagnetic iron oxide nanoparticles stabilized by alginate. Int J Pharm 2007; 333(1/2): 177-186.
39. Morales MA, Finotelli PV, Coaquira JAH, Rocha-Leão MHM, Diaz-Aguila C, Baggio-Saitovitch EM, Rossi AM. In situ synthesis and magnetic studies of iron oxide nanoparticles in calcium-alginate matrix for biomedical applications. Mater Sci Eng C 2008; 28(2): 253-257.
40. Roohi F, Lohrke J, Ide A, Schütz G, Dassler K. Studying the effect of particle size and coating type on the blood kinetics of superparamagnetic iron oxide nanoparticles. Int J Nanomed 2012; 7: 4447-4458.
41. Burtea C, Laurent S, Mahieu I, Larbanoix L, Roch A, Port M, Rousseaux O, Ballet S, Murariu O, Toubeau G, Corot C, Vander Elst L, Muller RN. In vitro biomedical applications of functionalized iron oxide nanoparticles, including those not related to magnetic properties. Contrast Media Mol Imaging 2011; 6(4): 236-250.
42. Kim DK, Zhang Y, Kehr J, Klason T, Bjelke B, Muhammed M. Characterization and MRI study of surfactant-coated superparamagnetic nanoparticles administered into the rat brain. J Magn Magn Mater 2001; 225(1/2): 256-261.
43. Shultz MD, Calvin S, Fatouros PP, Morrison SA, Carpenter EE. Enhanced ferrite nanoparticles as MRI contrast agents. J Magn Magn Mater 2007; 311(1): 464-468.
44. Gupta AK, Curtis ASG. Surface modified superparamagnetic nanoparticles for drug delivery: interaction studies with human fibroblasts in culture. J Mater Sci Mater Med 2004; 15(4): 493-496.
45. Kohler N, Fryxell GE, Zhang M. A bifunctional poly(ethylene glycol) silane immobilized on metallic oxide-based nanoparticles for conjugation with cell targeting agents. J Am Chem Soc 2004; 126(23): 7206-7211.
46. Kellar KE, Fujii DK, Gunther WHH, Briley-Sabo K, Bjornerod A, Spiller M, Koenig SH. Important considerations in the design of iron oxide nanoparticles as contrast agents for T1-weighted MRI and MRA. Acad Radiol 2002; 9(Suppl. 1): S34-S37.
47. Acar HYC, Garaas RS, Syud F, Bonitatebus P, Kulkarni AM. Superparamagnetic nanoparticles stabilized by polymerized PEGylated coatings. J Magn Magn Mater 2005; 293(1): 1-7.
48. Ngaboni Okassa L, Marchais H, Douziech-Eyrolles L, Cohen-Jonathan S, Soucé M, Dubois P, Chourpa I. Development and characterization of sub-micron poly(d, l-lactide-co-glycolide) particles loaded with magnetite/maghemite nanoparticles. Int J Pharm 2005; 302(1/2): 187-196.
49. Sander EA, Alb AM, Nauman EA, Reed WF, Dee KC. Solvent effects on the microstructure and properties of 75/25 poly(D, L-lactide-co-glycolide) tissue scaffolds. J Biomed Mater Res A 2004; 70A(3): 506-513.
50. Kopke RD, Wassel RA, Mondalek F, Grady B, Chen K, Liu J, Gibson D, Dormer KJ. Magnetic nanoparticles: inner ear targeted molecule delivery and middle ear implant. Audiol Neurotol 2005; 11(2): 123-133.
51. Mornet S, Portier J, Duguet E. A method for synthesis and functionalization of ultrasmall superparamagnetic covalent carriers based on maghemite and dextran. J Magn Magn Mater 2005; 293(1): 127-134.
52. Duguet EMS, Portier J. French Patent FR2855315. Chem Abstr 2004; 141: 405023.
53. Wagner S, Schnorr J, Pilgrimm H, Hamm B, Taupitz M. Monomer-coated very small superparamagnetic iron oxide particles as contrast medium for magnetic resonance imaging: preclinical in vivo characterization. Invest Radiol 2002; 37(4): 167-177.
54. Taupitz M, Wagner S, Schnorr J, Kravec I, Pilgrimm H, Bergmann-Fritsch H, Hamm B. Phase I clinical evaluation of citrate-coated monocrystalline very small superparamagnetic iron oxide particles as a new contrast medium for magnetic resonance imaging. Invest Radiol 2004; 39(7): 394-405.
55. Fauconnier N, Pons JN, Roger J, Bee A. Thiolation of maghemite nanoparticles by dimercaptosuccinic acid. J Colloid Interface Sci 1997; 194(2): 427-433.
56. Fauconnier N, Bee A, Roger J, Pons JN. Adsorption of gluconic and citric acids on maghemite particles in aqueous medium. Prog Colloid Polym Sci 1996; 100: 212-216.
57. Fauconnier N, Bée A, Roger J, Pons JN. Synthesis of aqueous magnetic liquids by surface complexation of maghemite nanoparticles. J Mol Liquids 1999; 83(1-3): 233-242.
58. Jung CW. Surface properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging 1995; 13(5): 675-691.
59. 4 nanoparticles and their biomedical applications. Biomaterials 2005; 26(7): 729-738.
60. Jung CW, Jacobs P. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging 1995; 13(5): 661-674.
61. Laurent S, Vander Elst L, Muller RN. Superparamagnetic iron oxide nanoparticles for MRI. In The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging (2nd edn). Wiley: Chichester, UK, 2013; 427-447.
62. Walczyk D, Bombelli FB, Monopoli MP, Lynch I, Dawson KA. What the cell 'sees' in bionanoscience. J Am Chem Soc 2010; 132(16): 5761-5768.
63. Lesniak A, Fenaroli F, Monopoli MP, Åberg C, Dawson KA, Salvati A. Effects of the presence or absence of a protein corona on silica nanoparticle uptake and impact on cells. ACS Nano 2012; 6(7): 5845-5857.
64. Monopoli MP, Walczyk D, Campbell A, Elia G, Lynch I, Baldelli Bombelli F, Dawson KA. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J Am Chem Soc 2011; 133(8): 2525-2534.
65. Jedlovszky-Hajdú A, Bombelli FB, Monopoli MP, Tombácz E, Dawson KA. Surface coatings shape the protein corona of SPIONs with relevance to their application in vivo. Langmuir 2012; 28(42): 14983-14991.
66. Laurent S, Dutz S, Häfeli UO, Mahmoudi M. Magnetic fluid hyperthermia: focus on superparamagnetic iron oxide nanoparticles. Adv Colloid Interface Sci 2011; 166(1): 8-23.
67. Larbanoix L, Burtea C, Laurent S, Van Leuven F, Toubeau G, Elst LV, Muller RN. Potential amyloid plaque-specific peptides for the diagnosis of Alzheimer's disease. Neurobiol Aging 2010; 31(10): 1679-1689.
68. Abdolahi M, Shahbazi-Gahrouei D, Laurent S, Sermeus C, Firozian F, Allen BJ, Boutry S, Muller RN. Synthesis and in vitro evaluation of MR molecular imaging probes using J591 mAb-conjugated SPIONs for specific detection of prostate cancer. Contrast Media Mol Imaging 2013; 8(2): 175-184.
69. Mirshafiee V, Mahmoudi M, Lou K, Cheng J, Kraft ML. Protein corona significantly reduces active targeting yield. Chem Commun 2013; 49(25): 2557-2559.
70. Salvati A, Pitek AS, Monopoli MP, Prapainop K, Bombelli FB, Hristov DR, Kelly PM, Aberg C, Mahon E, Dawson KA. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol 2013; 8(2): 137-143.
71. Amiri H, Bordonali L, Lascialfari A, Wan S, Monopoli MP, Lynch I, Laurent S, Mahmoudi M. Protein corona affects the relaxivity and MRI contrast efficiency of magnetic nanoparticles. Nanoscale 2013; 5(18): 8656-8665.
72. Wang J, Sui M, Fan W. Nanoparticles for tumor targeted therapies and their pharmacokinetics. Curr Drug Metab 2010; 11(2): 129-141.
73. Mahon E, Salvati A, Bombelli FB, Lynch I, Dawson KA. Designing the nanoparticle-biomolecule interface for "targeting and therapeutic delivery". J. Controlled Release 2012; 161: 164-174.
74. Vogl TJ, Hammerstingl R, Schwarz W, Mack MG, Müller PK, Pegios W, Keck H, Eibl-Eibesfeldt A, Hoelzl J, Woessmer B, Bergman C, Felix R. Superparamagnetic iron oxide-enhanced versus gadolinium-enhanced MR imaging for differential diagnosis of focal liver lesions. Radiology 1996; 198(3): 881-887.
75. Namkung S, Zech CJ, Helmberger T, Reiser MF, Schoenberg SO. Superparamagnetic iron oxide (SPIO)-enhanced liver MRI with ferucarbotran: efficacy for characterization of focal liver lesions. J Magn Reson Imaging 2007; 25(4): 755-765.
76. Wang YXJ, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 2001; 11(11): 2319-2331.
77. Gupta AK, Naregalkar RR, Vaidya VD, Gupta M. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Nanomedicine 2007; 2(1): 23-39.
78. Semelka RC, Helmberger TKG. State of the art: contrast agents for MR imaging of the liver. Radiology 2001; 218(1): 27-38.
79. Weissleder R, Lee AS, Khaw BA, Shen T, Brady TJ. Antimyosin-labeled monocrystalline iron oxide allows detection of myocardial infarct: MR antibody imaging. Radiology 1992; 182(2): 381-385.
80. Suwa T, Ozawa S, Ueda M, Ando N, Kitajima M. Magnetic resonance imaging of esophageal squamous cell carcinoma using magnetite particles coated with anti-epidermal growth factor receptor antibody. Int J Cancer 1998; 75(4): 626-634.
81. Wadghiri YZ, Sigurdsson EM, Sadowski M, Elliott JI, Li Y, Scholtzova H, Tang CY, Aguinaldo G, Pappolla M, Duff K, Wisniewski T, Turnbull DH. Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med 2003; 50(2): 293-302.
82. Reimer P, Weissleder R, Shen T, Knoefel WT, Brady TJ. Pancreatic receptors: initial feasibility studies with a targeted contrast agent for MR imaging. Radiology 1994; 193(2): 527-531.
83. Jung HI, Kettunen MI, Davletov B, Brindle KM. Detection of apoptosis using the C2A domain of synaptotagmin I. Bioconjugate Chem 2004; 15(5): 983-987.
84. Artemov D, Mori N, Okollie B, Bhujwalla ZM. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med 2003; 49(3): 403-408.
85. Bulte JWM, Hoekstra Y, Kamman RL, Magin RL, Webb AG, Briggs RW, Go KG, Hulstaert CE, Miltenyi S, The TH, De Leij L. Specific MR imaging of human lymphocytes by monoclonal antibody-guided dextran-magnetite particles. Magn Reson Med 1992; 25(1): 148-157.
86. Go KG, Bulte JWM, De Ley L, The TH, Kamman RL, Hulstaert CE, Blaauw EH, Ma LD. Our approach towards developing a specific tumour-targeted MRI contrast agent for the brain. Eur J Radiol 1993; 16(3): 171-175.
87. Sun EY, Josephson L, Kelly KA, Weissleder R. Development of nanoparticle libraries for biosensing. Bioconjugate Chem 2006; 17(1): 109-113.
88. Renshaw PF, Owen CS, Evans AE, Leigh JS Jr. Immunospecific NMR contrast agents. Magn Reson Imaging 1986; 4(4): 351-357.
89. Suzuki M, Shinkai M, Kamihira M, Kobayashi T. Preparation and characteristics of magnetite-labelled antibody with the use of poly(ethylene glycol) derivatives. Biotechnol Appl Biochem 1995; 21(3): 335-345.
90. Zhou J, Leuschner C, Kumar C, Hormes JF, Soboyejo WO. Sub-cellular accumulation of magnetic nanoparticles in breast tumors and metastases. Biomaterials 2006; 27(9): 2001-2008.
91. Leuschner C, Kumar C, Urbina MO, Zhou J, Soboyejo W, Hansel W, Hormes F. The use of ligand conjugated superparamagnetic iron oxide nanoparticles (SPION) for early detection of metastases. Technical Proceedings of the 2005 NSTI Nanotechnology Conference and Trade Show, Vol. 1. Boca Raton, FL: CRC Press, 2007; 5-6.
92. Zhang C, Jugold M, Woenne EC, Lammers T, Morgenstern B, Mueller MM, Zentgraf H, Bock M, Eisenhut M, Semmler W, Kiessling F. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res 2007; 67(4): 1555-1562.
93. Peng ZG, Hidajat K, Uddin MS. Adsorption of bovine serum albumin on nanosized magnetic particles. J Colloid Interface Sci 2004; 271(2): 277-283.
94. Mehta RV, Upadhyay RV, Charles SW, Ramchand CN. Direct binding of protein to magnetic particles. Biotechnol Tech 1997; 11(7): 493-496.
95. Kresse M, Wagner S, Pfefferer D, Lawaczeck R, Elste V, Semmler W. Targeting of ultrasmall superparamagnetic iron oxide (USPIO) particles to tumor cells in vivo by using transferrin receptor pathways. Magn Reson Med 1998; 40(2): 236-242.
96. Cengelli F, Maysinger D, Tschudi-Monnet F, Montet X, Corot C, Petri-Fink A, Hofmann H, Juillerat-Jeanneret L. Interaction of functionalized superparamagnetic iron oxide nanoparticles with brain structures. J Pharmacol Exp Ther 2006; 318(1): 108-116.
97. Zhao M, Beauregard DA, Loizou L, Davletov B, Brindle KM. Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat Med 2001; 7(11): 1241-1244.
98. Weissleder R, Lee AS, Fischman AJ, Reimer P, Shen T, Wilkinson R, Callahan RJ, Brady TJ. Polyclonal human immunoglobulin G labeled with polymeric iron oxide: antibody MR imaging. Radiology 1991; 181(1): 245-249.
99. Toma A, Otsuji E, Kuriu Y, Okamoto K, Ichikawa D, Hagiwara A, Ito H, Nishimura T, Yamagishi H. Monoclonal antibody A7-superparamagnetic iron oxide as contrast agent of MR imaging of rectal carcinoma. Br J Cancer 2005; 93(1): 131-136.
100. Li M, Xu H, Zuo J, Ji A, He B, Pang Y, Huang J, Niu R. Preparation of dextran immunological magnetic nanoparticles and their application to combined targeting carrier. Sci China B: Chem 1996; 39(6): 577-584.
101. Remsen LG, McCormick CI, Roman-Goldstein S, Nilaver G, Weissleder R, Bogdanov A, Hellström KE, Hellström I, Kroll RA, Neuwelt EA. MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: the potential for noninvasive diagnosis. Am J Neuroradiol 1996; 17(3): 411-418.
102. Funovics MA, Kapeller B, Hoeller C, Su HS, Kunstfeld R, Puig S, Macfelda K. MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents. Magn Reson Imaging 2004; 22(6): 843-850.
103. Sonvico F, Mornet S, Vasseur S, Dubernet C, Jaillard D, Degrouard J, Hoebeke J, Duguet E, Colombo P, Couvreur P. Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: synthesis, physicochemical characterization, and in vitro experiments. Bioconjugate Chem 2005; 16(5): 1181-1188.
104. Zhang Y, Zhang J. Surface modification of monodisperse magnetite nanoparticles for improved intracellular uptake to breast cancer cells. J Colloid Interface Sci 2005; 283(2): 352-357.
105. Josephson L, Tung CH, Moore A, Weissleder R. High-efficiency intracellular magnetic labeling with novel superparamagnetic-tat peptide conjugates. Bioconjugate Chem 1999; 10(2): 186-191.
106. Hogemann D, Josephson L, Weissleder R, Basilion JP. Improvement of MRI probes to allow efficient detection of gene expression. Bioconjugate Chem 2000; 11(6): 941-946.
107. Högemann-Savellano D, Bost E, Blondet C, Sato F, Abe T, Josephson L, Weissleder R, Gaudet J, Sgroi D, Peters PJ, Basilion JP. The transferrin receptor: a potential molecular imaging marker for human cancer. Neoplasia 2003; 5(6): 495-506.
108. Won Kang H, Josephson L, Petrovsky A, Weissleder R, Bogdanov A Jr. Magnetic resonance imaging of inducible E-selectin expression in human endothelial cell culture. Bioconjugate Chem 2002; 13(1): 122-127.
109. Sun C, Sze R, Zhang M. Folic acid-PEG conjugated superparamagnetic nanoparticles for targeted cellular uptake and detection by MRI. J Biomed Mater Res A 2006; 78(3): 550-557.
110. Josephson L, Kircher MF, Mahmood U, Tang Y, Weissleder R. Near-infrared fluorescent nanoparticles as combined MR/optical imaging probes. Bioconjugate Chem 2002; 13(3): 554-560.
111. Dodd CH, Hsu HC, Chu WJ, Yang P, Zhang HG, Mountz JD Jr, Zinn K, Forder J, Josephson L, Weissleder R, Mountz JM, Mountz JD. Normal T-cell response and in vivo magnetic resonance imaging of T cells loaded with HIV transactivator-peptide-derived superparamagnetic nanoparticles. J Immunol Methods 2001; 256(1/2): 89-105.
112. Papisov MI, Bogdanov A Jr, Schaffer B, Nossiff N, Shen T, Weissleder R, Brady TJ. Colloidal magnetic resonance contrast agents: effect of particle surface on biodistribution. J Magn Magn Mater 1993; 122(1-3): 383-386.
113. Koch AM, Reynolds F, Merkle HP, Weissleder R, Josephson L. Transport of surface-modified nanoparticles through cell monolayers. ChemBioChem 2005; 6(2): 337-345.
114. Funovics M, Montet X, Reynolds F, Weissleder R, Josephson L. Nanoparticles for the optical imaging of tumor E-selectin. Neoplasia 2005; 7(10): 904-911.
115. Kircher MF, Josephson L, Weissleder R. Ratio imaging of enzyme activity using dual wavelength optical reporters. Mol Imaging 2002; 1(2): 89-95.
116. Kircher MF, Weissleder R, Josephson L. A dual fluorochrome probe for imaging proteases. Bioconjugate Chem 2004; 15(2): 242-248.
117. Moore A, Medarova Z, Potthast A, Dai G. In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res 2004; 64(5): 1821-1827.
118. Högemann D, Ntziachristos V, Josephson L, Weissleder R. High throughput magnetic resonance imaging for evaluating targeted nanoparticle probes. Bioconjugate Chem 2002; 13(1): 116-121.
119. Tsourkas A, Shinde-Patil VR, Kelly KA, Patel P, Wolley A, Allport JR, Weissleder R. In vivo imaging of activated endothelium using an anti-VCAM-1 magnetooptical probe. Bioconjugate Chem 2005; 16(3): 576-581.
120. Montet X, Funovics M, Montet-Abou K, Weissleder R, Josephson L. Multivalent effects of RGD peptides obtained by nanoparticle display. J Med Chem 2006; 49(20): 6087-6093.
121. Montet X, Montet-Abou K, Reynolds F, Weissleder R, Josephson L. Nanoparticle imaging of integrins on tumor cells. Neoplasia 2006; 8(3): 214-222.
122. Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, Weissleder R. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res 2005; 96(3): 327-336.
123. Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol 2005; 23(11): 1418-1423.
124. Kircher MF, Mahmood U, King RS, Weissleder R, Josephson L. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res 2003; 63(23): 8122-8125.
125. Halbreich A, Roger J, Pons JN, Da Silva MdF, Hasmonay E, Roudier M, Boynard M, Sestier C, Amri A, Geldwerth D, Fertil B, Bacri JC, Sabolovic D. Magnetic maghemite nanoparticles: their preparation, properties, and application in cell sorting and characterization of cellular membranes in vitro. Scientific and Clinical Applications of Magnetic Carriers. Plenum: New York, 1997; 399-417.
126. Jun YW, Huh YM, Choi JS, Lee JH, Song HT, Kim S, Yoon S, Kim KS, Shin JS, Suh JS, Cheon J. Nanoscale size effect of magnetic nanocrystals and their utilisation for cancer diagnosis via magnetic resonance imaging. J Am Chem Soc 2005; 127(16): 5732-5733.
127. Huh YM, Jun YW, Song HT, Kim S, Choi JS, Lee JH, Yoon S, Kim KS, Shin JS, Suh JS, Cheon J. In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals. J Am Chem Soc 2005; 127(35): 12387-12391.
128. Halbreich A, Sabolovic D, Sestier C, Amri A, Pons JN, Roger J, Geldwerth D. Annexin V binding to mouse erythrocytes following infection with Plasmodium parasites [2]. Parasitol Today 1996; 12(7): 292-293.
129. Sestier C, Sabolovic D, Geldwerth D, Moumaris M, Roger J, Pons JN, Halbreich A. Use of annexin V-ferrofluid to enumerate erythrocytes damaged in various pathologies or during storage in vitro. C R Acad Sci III 1995; 318(11): 1141-1146.
130. Roger J, Pons JN, Massart R, Halbreich A, Bacri JC. Some biomedical applications of ferrofluids. Eur Phys J Appl Phys 1999; 5(3): 321-325.
131. Halbreich A, Roger J, Pons JN, Geldwerth D, Da Silva MF, Roudier M, Bacri JC. Biomedical applications of maghemite ferrofluid. Biochimie 1998; 80(5/6): 379-390.
132. Whitehead RA, Chagnon MS, Groman EV, Josephson L. Magnetic particles for use in separations. US Patent 1987; 4: 695-392.
133. Bridot J-L, Stanicki D, Laurent S, Boutry S, Gossuin Y, Leclère P, Lazzaroni R, Vander Elst L, Muller RN. New carboxysilane coated iron oxide nanoparticles for non-specific cell labelling. Contrast Media Mol Imaging 2013; 8: 466-474.
134. Zhang Y, Kohler N, Zhang M. Intracellular uptake of poly(ethylene glycol) and folic acid modified magnetite nanoparticles. Mater Res Soc Proc 2001; 676: Y9.8.1-Y9.8.5.
135. Liu X, Xing J, Guan Y, Shan G, Liu H. Synthesis of amino-silane modified superparamagnetic silica supports and their use for protein immobilization. Colloids Surf A: Physicochem Eng Aspects 2004; 238(1-3): 127-131.
136. Sun EY, Josephson L, Weissleder R. 'Clickable' nanoparticles for targeted imaging. Mol Imaging 2006; 5(2): 122-128.
137. Müller-Schulte DFF, Lueken H, De Cuyper M. Neuer Ansatz für die AIDS-Therapie unter Verwendung superparamagnetischer Nanopartikel. Alma Mater Aquensis 1995; 31: 174-187.
138. Shinkai M, Suzuki M, Iijima S, Kobayashi T. Antibody-conjugated magnetoliposomes for targeting cancer cells and their application in hyperthermia. Biotechnol Applied Biochem 1995; 21(2): 125-137.
139. Sun EY, Josephson L, Weissleder R. 'Clickable' nanoparticles for targeted imaging. Mol Imaging 2006; 5(2): 122-128.
140. Domingo JC, Mercadal M, Petriz J, De Madariaga MA. Preparation of PEG-grafted immunomagnetoliosomes entrapping citrate stabilized magnetite particles and their application in CD34+ cell sorting. J Microencapsul 2001; 18(1): 41-54.
141. Ito A, Kuga Y, Honda H, Kikkawa H, Horiuchi A, Watanabe Y, Kobayashi T. Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia. Cancer Lett 2004; 212(2): 167-175.
142. Ito A, Ino K, Kobayashi T, Honda H. The effect of RGD peptide-conjugated magnetite cationic liposomes on cell growth and cell sheet harvesting. Biomaterials 2005; 26(31): 6185-6193.
143. Hodenius M, De Cuyper M, Desender L, Müller-Schulte D, Steigel A, Lueken H. Biotinylated Stealth® magnetoliposomes. Chem Phys Lipids 2002; 120(1/2): 75-85.
144. Nitin N, LaConte LEW, Zurkiya O, Hu X, Bao G. Functionalization and peptide-based delivery of magnetic nanoparticles as an intracellular MRI contrast agent. J Biol Inorg Chem 2004; 9(6): 706-712.
145. Nasongkla N, Bey E, Ren J, Ai H, Khemtong C, Guthi JS, Chin SF, Sherry AD, Boothman DA, Gao J. Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett 2006; 6(11): 2427-2430.
146. Rennen HJ, Boerman OC, Oyen WJ, Corstens FH. Imaging infection/inflammation in the new millennium. Eur J Nucl Med 2001; 28(2): 241-252.
147. Kooi M, Cappendijk V, Cleutjens K, Kessels A, Kitslaar P, Borgers M, Frederik P, Daemen M, Van Engelshoven J. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 2003; 107(19): 2453-2458.
148. Beckmann N, Cannet C, Fringeli-Tanner M, Baumann D, Pally C, Bruns C, Zerwes HG, Andriambeloson E, Bigaud M. Macrophage labeling by SPIO as an early marker of allograft chronic rejection in a rat model of kidney transplantation. Magn Reson Med 2003; 49(3): 459-467.
149. Barber PA, Foniok T, Kirk D, Buchan AM, Laurent S, Boutry S, Muller RN, Hoyte L, Tomanek B, Tuor UI. MR molecular imaging of early endothelial activation in focal ischemia. Ann Neurol 2004; 56(1): 116-120.
150. Tanaka Y. The role of chemokines and adhesion molecules in the pathogenesis of rheumatoid arthritis. Drugs Today (Barc) 2001; 37(7): 477-484.
151. Khatib A-M, Kontogiannea M, Fallavollita L, Jamison B, Meterissian S, Brodt P. Rapid induction of cytokine and E-selectin expression in the liver in response to metastatic tumor cells. Cancer Res 1999; 59(6): 1356-1361.
152. Menger MD, Vollmar B. Role of microcirculation in transplantation. Microcirculation 2000; 7(5): 291-306.
153. Dousset V, Delalande C, Ballarino L, Quesson B, Seilhan D, Coussemacq M, Thiaudiére E, Brochet B, Canioni P, Caillé JM. In vivo macrophage activity imaging in the central nervous system detected by magnetic resonance. Magn Reson Med 1999; 41(2): 329-333.
154. Dousset V, Gomez C, Petry KG, Delalande C, Caille J-M. Dose and scanning delay using USPIO for central nervous system macrophage imaging. Magn Reson Mater Phys Biol Med 1999; 8(3): 185-189.
155. Fleige G, Nolte C, Synowitz M, Seeberger F, Kettenmann H, Zimmer C. Magnetic labeling of activated microglia in experimental gliomas. Neoplasia 2001; 3(6): 489.
156. Rausch M, Hiestand P, Baumann D, Cannet C, Rudin M. MRI-based monitoring of inflammation and tissue damage in acute and chronic relapsing EAE. Magn Reson Med 2003; 50(2): 309-314.
157. Ruehm SG, Corot C, Vogt P, Kolb S, Debatin JF. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation 2001; 103(3): 415-422.
158. Kang HW, Josephson L, Petrovsky A, Weissleder R, Bogdanov A. Magnetic resonance imaging of inducible E-selectin expression in human endothelial cell culture. Bioconjugate Chem 2002; 13(1): 122-127.
159. -/- mice: a pilot study. Invest Radiol 2009; 44(3): 151-158.
160. 3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res 2003; 63(18): 5838-5843.
161. Albelda SM, Buck CA. Integrins and other cell adhesion molecules. FASEB J 1990; 4(11): 2868-2880.
162. x oligosaccharide. J Cell Biol 1992; 117(4): 895-902.
163. Vestweber D, Blanks JE. Mechanisms that regulate the function of the selectins and their ligands. Physiol Rev 1999; 79(1): 181-213.
164. Boutry S, Laurent S, Elst LV, Muller RN. Specific E-selectin targeting with a superparamagnetic MRI contrast agent. Contrast Media Mol Imaging 2006; 1(1): 15-22.
165. Laurent S, Vander Elst L, Fu Y, Muller RN. Synthesis and physicochemical characterization of Gd-DTPA-B (sLex) A, a new MRI contrast agent targeted to inflammation. Bioconjugate Chem 2004; 15(1): 99-103.
166. Sibson NR, Blamire AM, Bernades-Silva M, Laurent S, Boutry S, Muller RN, Styles P, Anthony DC. MRI detection of early endothelial activation in brain inflammation. Magn Reson Med 2004; 51(2): 248-252.
167. Boutry S, Burtea C, Laurent S, Toubeau G, Vander Elst L, Muller RN. Magnetic resonance imaging of inflammation with a specific selectin-targeted contrast agent. Magn Reson Med 2005; 53(4): 800-807.
168. Serda RE, Adolphi NL, Bisoffi M, Sillerud LO. Targeting and cellular trafficking of magnetic nanoparticles for prostate cancer imaging. Mol Imaging 2007; 6(4): 277-288.
169. Kou G, Wang S, Cheng C, Gao J, Li B, Wang H, Qian W, Hou S, Zhang D, Dai J, Gu H, Guo Y. Development of SM5-1-conjugated ultrasmall superparamagnetic iron oxide nanoparticles for hepatoma detection. Biochem Biophys Res Commun 2008; 374(2): 192-197.
170. Chen TJ, Cheng TH, Chen CY, Hsu SC, Cheng TL, Liu GC, Wang YM. Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI. J Biol Inorg Chem 2009; 14(2): 253-260.
171. Yang H-M, Park CW, Woo M-A, Kim MI, Jo YM, Park HG, Kim J-D. HER2/neu antibody conjugated poly(amino acid)-coated iron oxide nanoparticles for breast cancer MR imaging. Biomacromolecules 2010; 11(11): 2866-2872.
172. Song E-Q, Hu J, Wen C-Y, Tian Z-Q, Yu X, Zhang Z-L, Shi Y-B, Pang D-W. Fluorescent-magnetic-biotargeting multifunctional nanobioprobes for detecting and isolating multiple types of tumor cells. ACS Nano 2011; 5(2): 761-770.
173. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987; 47(12): 3039-3051.
174. McNeil SE. Nanotechnology for the biologist. J Leukoc Biol 2005; 78(3): 585-594.
175. Yang L, Mao H, Wang YA, Cao Z, Peng X, Wang X, Duan H, Ni C, Yuan Q, Adams G, Smith MQ, Wood WC, Gao X, Nie S. Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small 2009; 5(2): 235-243.
176. Yang L, Mao H, Cao Z, Wang YA, Peng X, Wang X, Sajja HK, Wang L, Duan H, Ni C, Staley CA, Wood WC, Gao X, Nie S. Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles. Gastroenterology 2009; 136(5): 1514-1525.
177. Chatzistamou L, Schally AV, Nagy A, Armatis P, Szepeshazi K, Halmos G. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207. Clin Cancer Res 2000; 6(10): 4158-4165.
178. Leuschner C, Kumar CS, Hansel W, Soboyejo W, Zhou J, Hormes J. LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases. Breast Cancer Res Treat 2006; 99(2): 163-176.
179. Ichikawa T, Hogemann D, Saeki Y, Tyminski E, Terada K, Weissleder R, Chiocca EA, Basilion JP. MRI of transgene expression: correlation to therapeutic gene expression. Neoplasia 2002; 4(6): 523-530.
180. Moore A, Basilion JP, Chiocca EA, Weissleder R. Measuring transferrin receptor gene expression by NMR imaging. Biochim Biophys Acta 1998; 24(3): 239-249.
181. Weissleder R, Moore A, Mahmood U, Bhorade R, Benveniste H, Chiocca EA, Basilion JP. In vivo magnetic resonance imaging of transgene expression. Nat Med 2000; 6(3): 351-355.
182. Low PS, Henne WA, Doorneweerd DD. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res 2008; 41(1): 120-129.
183. Choi H, Choi SR, Zhou R, Kung HF, Chen IW. Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad Radiol 2004; 11(9): 996-1004.
184. Sun C, Sze R, Zhang M. Folic acid-PEG conjugated superparamagnetic nanoparticles for targeted cellular uptake and detection by MRI. J Biomed Mater Res A 2006; 78(3): 550-557.
185. Chen H, Gu Y, Hub Y, Qian Z. Characterization of pH- and temperature-sensitive hydrogel nanoparticles for controlled drug release. Parenter Drug Assoc J Pharm Sci Technol 2007; 61(4): 303-313.
186. Shen TT, Bogdanov A Jr, Bogdanova A, Poss K, Brady TJ, Weissleder R. Magnetically labeled secretin retains receptor affinity to pancreas acinar cells. Bioconjugate Chem 1996; 7(3): 311-316.
187. Sunderland CJ, Steiert M, Talmadge JE, Derfus AM, Barry SE. Targeted nanoparticles for detecting and treating cancer. Drug Dev Res 2006; 67(1): 70-93.
188. Zhang C, Jugold M, Woenne EC, Lammers T, Morgenstern B, Mueller MM, Zentgraf H, Bock M, Eisenhut M, Semmler W, Kiessling F. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res 2007; 67(4): 1555-1562.
189. Liu C, Liu DB, Long GX, Wang JF, Mei Q, Hu GY, Qiu H, Hu GQ. Specific targeting of angiogenesis in lung cancer with RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a 4.7T magnetic resonance scanner. Chin Med J 2013; 126(12): 2242-2247.
190. Burtea C, Laurent S, Murariu O, Rattat D, Toubeau G, Verbruggen A, Vansthertem D, Vander Elst L, Muller RN. Molecular imaging of alpha v beta3 integrin expression in atherosclerotic plaques with a mimetic of RGD peptide grafted to Gd-DTPA. Cardiovasc Res 2008; 78(1): 148-157.
191. Rerat V, Laurent S, Burtea C, Driesschaert B, Pourcelle V, Vander Elst L, Muller RN, Marchand-Brynaert J. Ultrasmall particle of iron oxide-RGD peptidomimetic conjugate: synthesis and characterisation. Bioorganic Med Chem Lett 2010; 20(6): 1861-1865.
192. 4 nanoparticles and their specific targeting to integrin alpha(v)beta3-rich tumor cells. J Am Chem Soc 2008; 130(24): 7542-7543.
193. Bamrungsap S, Chen T, Shukoor MI, Chen Z, Sefah K, Chen Y, Tan W. Pattern recognition of cancer cells using aptamer-conjugated magnetic nanoparticles. ACS Nano 2012; 6(5): 3974-3981.
194. Medley CD, Bamrungsap S, Tan W, Smith JE. Aptamer-conjugated nanoparticles for cancer cell detection. Anal Chem 2011; 83(3): 727-734.
195. Smith JE, Medley CD, Tang Z, Shangguan D, Lofton C, Tan W. Aptamer-conjugated nanoparticles for the collection and detection of multiple cancer cells. Anal Chem 2007; 79(8): 3075-3082.
196. Yu MK, Kim D, Lee IH, So JS, Jeong YY, Jon S. Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles. Small 2011; 7(15): 2241-2249.
197. Wang AZ, Bagalkot V, Vasilliou CC, Gu F, Alexis F, Zhang L, Shaikh M, Yuet K, Cima MJ, Langer R, Kantoff PW, Bander NH, Jon S, Farokhzad OC. Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem 2008; 3(9): 1311-1315.
198. Yigit MV, Mazumdar D, Kim H-K, Lee JH, Odintsov B, Lu Y. Smart 'turn-on' magnetic resonance contrast agents based on aptamer-functionalized superparamagnetic iron oxide nanoparticles. ChemBioChem 2007; 8(14): 1675-1678.
199. Yigit MV, Mazumdar D, Lu Y. MRI Detection of thrombin with aptamer functionalized superparamagnetic iron oxide nanoparticles. Bioconjugate Chem 2008; 19(2): 412-417.
200. Reddy LH, Couvreur P. Nanotechnology for therapy and imaging of liver diseases. J Hepatol 2011; 55(6): 1461-1466.
201. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115(2): 209-218.
202. Faria SC, Ganesan K, Mwangi I, Shiehmorteza M, Viamonte B, Mazhar S, Peterson M, Kono Y, Santillan C, Casola G, Sirlin CB. MR imaging of liver fibrosis: current state of the art. Radiographics 2009; 29(6): 1615-1635.
203. Rosen JE, Chan L, Shieh D-B, Gu FX. Iron oxide nanoparticles for targeted cancer imaging and diagnostics. Nanomed Nanotechnol Biol Med 2012; 8(3): 275-290.
204. Qiao R, Yang C, Gao M. Superparamagnetic iron oxide nanoparticles: from preparations to in vivo MRI applications. J Mater Chem 2009; 19(35): 6274-6293.
205. Gandhi SN, Brown MA, Wong JG, Aguirre DA, Sirlin CB. MR contrast agents for liver imaging: what, when, how. Radiographics 2006; 26(6): 1621-1636.
206. Ma HL, Xu YF, Qi XR, Maitani Y, Nagai T. Superparamagnetic iron oxide nanoparticles stabilized by alginate: pharmacokinetics, tissue distribution, and applications in detecting liver cancers. Int J Pharm 2008; 354(1/2): 217-226.
207. Clement O, Frija G, Chambon C, Schouman-Clayes E, Mosnier JF, Poupon MF, Balkau B. Liver tumors in cirrhosis: experimental study with SPIO-enhanced MR imaging. Radiology 1991; 180(1): 31-36.
208. Tanimoto A, Kuribayashi S. Application of superparamagnetic iron oxide to imaging of hepatocellular carcinoma. Eur J Radiol 2006; 58(2): 200-216.
209. Aguirre DA, Behling CA, Alpert E, Hassanein TI, Sirlin CB. Liver fibrosis: noninvasive diagnosis with double contrast material-enhanced MR imaging. Radiology 2006; 239(2): 425-437.
210. Wang YX, Xuan S, Port M, Idee JM. Recent advances in superparamagnetic iron oxide nanoparticles for cellular imaging and targeted therapy research. Curr Pharm Des 2013: 6575-6593.
211. Zhang H, Ma Y, Sun XL. Recent developments in carbohydrate-decorated targeted drug/gene delivery. Med Res Rev 2010; 30(2): 270-289.
212. Lee C-M, Jeong H-J, Kim E-M, Kim DW, Lim ST, Kim HT, Park I-K, Jeong YY, Kim JW, Sohn M-H. Superparamagnetic iron oxide nanoparticles as a dual imaging probe for targeting hepatocytes in vivo. Magn Reson Med 2009; 62(6): 1440-1446.
213. Zhao M, Beauregard DA, Loizou L, Davletov B, Brindle KM. Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat Med 2001; 7(11): 1241-1244.
214. Radermacher KA, Boutry S, Laurent S, Elst LV, Mahieu I, Bouzin C, Magat J, Gregoire V, Feron O, Muller RN, Jordan BF, Gallez B. Iron oxide particles covered with hexapeptides targeted at phosphatidylserine as MR biomarkers of tumor cell death. Contrast Media Mol Imaging 2010; 5(5): 258-267.
215. Vu-Quang H, Muthiah M, Lee HJ, Kim Y-K, Rhee JH, Lee J-H, Cho C-S, Choi Y-J, Jeong YY, Park I-K. Immune cell-specific delivery of beta-glucan-coated iron oxide nanoparticles for diagnosing liver metastasis by MR imaging. Carbohydr Polym 2012; 87(2): 1159-1168.
216. Kolosnjaj-Tabi J, Wilhelm C, Clement O, Gazeau F. Cell labeling with magnetic nanoparticles: opportunity for magnetic cell imaging and cell manipulation. J Nanobiotechnol 2013; 11(Suppl 1): S7.
217. Luciani A, Parouchev A, Smirnov P, Braga G, Wilhelm C, Gazeau F, Boudechiche L, L'Hermine-Coulomb A, Dagher I, Franco D, Rahmouni A, Hadchouel M, Weber A, Clement O. In vivo imaging of transplanted hepatocytes with a 1.5-T clinical MRI system - initial experience in mice. Eur Radiol 2008; 18(1): 59-69.
218. Maccioni F, Colaiacomo MC, Parlanti S. Ulcerative colitis: value of MR imaging. Abdom Imaging 2005; 30(5): 584-592.
219. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 2001; 11(11): 2319-2331.
220. Hahn PF, Stark DD, Lewis JM, Saini S, Elizondo G, Weissleder R, Fretz CJ, Ferrucci JT. First clinical trial of a new superparamagnetic iron oxide for use as an oral gastrointestinal contrast agent in MR imaging. Radiology 1990; 175(3): 695-700.
221. Wang Y-XJ. Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application. Quant Imaging Med Surg 2011; 1(1): 35-40.
222. D'Arienzo A, Scaglione G, Vicinanza G, Manguso F, Bennato R, Belfiore G, Imbriaco M, Mazzacca G. Magnetic resonance imaging with ferumoxil, a negative superparamagnetic oral contrast agent, in the evaluation of ulcerative colitis. Am J Gastroenterol 2000; 95(3): 720-724.
223. Xiao B, Merlin D. Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease. Expert Opin Drug Deliv 2012; 9(11): 1393-1407.
224. Crater JS, Carrier RL. Barrier properties of gastrointestinal mucus to nanoparticle transport. Macromol Biosci 2010; 10(12): 1473-1483.
225. Kenzaoui BH, Vila MR, Miquel JM, Cengelli F, Juillerat-Jeanneret L. Evaluation of uptake and transport of cationic and anionic ultrasmall iron oxide nanoparticles by human colon cells. Int J Nanomedicine 2012; 7: 1275-1286.
226. Elias A, Tsourkas A. Imaging circulating cells and lymphoid tissues with iron oxide nanoparticles. Hematology 2009; 2009(1): 720-726.
227. Jahan N, Narayanan P, Rockall A. Magnetic resonance lymphography in gynaecological malignancies. Cancer Imaging 2010; 10: 85-96.
228. Koh DM, Cook GJ, Husband JE. New horizons in oncologic imaging. N Engl J Med 2003; 348(25): 2487-2488.
229. Benedetti-Panici P, Maneschi F, Scambia G, Greggi S, Cutillo G, D'Andrea G, Rabitti C, Coronetta F, Capelli A, Mancuso S. Lymphatic spread of cervical cancer: an anatomical and pathological study based on 225 radical hysterectomies with systematic pelvic and aortic lymphadenectomy. Gynecol Oncol 1996; 62(1): 19-24.
230. Hövels AM, Heesakkers RAM, Adang EM, Jager GJ, Strum S, Hoogeveen YL, Severens JL, Barentsz JO. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008; 63(4): 387-395.
231. Islam T, Harisinghani MG. Overview of nanoparticle use in cancer imaging. Cancer Biomark 2009; 5(2): 61-67.
232. Weissleder R, Bogdanov A, Neuwelt EA, Papisov M. Long-circulating iron oxides for MR imaging. Adv Drug Deliv Rev 1995; 16(2-3): 321-334.
233. Bellin M-F, Beigelman C, Precetti-Morel S. Iron oxide-enhanced MR lymphography: initial experience. Eur J Radiol 2000; 34(3): 257-264.
234. Schroeder A, Heller DA, Winslow MM, Dahlman JE, Pratt GW, Langer R, Jacks T, Anderson DG. Treating metastatic cancer with nanotechnology. Nat Rev Cancer 2012; 12(1): 39-50.
235. Raynal I, Prigent P, Peyramaure S, Najid A, Rebuzzi C, Corot C. Macrophage Endocytosis of Superparamagnetic Iron Oxide Nanoparticles: Mechanisms and Comparison of Ferumoxides and Ferumoxtran-10. Invest. Radiol 2004; 39(1): 56-63.
236. Ferrucci JT, Stark DD. Iron oxide-enhanced MR imaging of the liver and spleen: review of the first 5 years. Am J Roentgenol 1990; 155(5): 943-950.
237. Daldrup-Link H, Rummeny E, Ihssen B, Kienast J, Link T. Iron-oxide-enhanced MR imaging of bone marrow in patients with non-Hodgkin's lymphoma: differentiation between tumor infiltration and hypercellular bone marrow. Eur Radiol 2002; 12(6): 1557-1566.
238. Jung CW, Rogers JM, Groman EV. Lymphatic mapping and sentinel node location with magnetite nanoparticles. J Magn Magn Mater 1999; 194(1-3): 210-216.
239. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348(25): 2491-2499.
240. Deserno WM, Harisinghani MG, Taupitz M, Jager GJ, Witjes JA, Mulders PF. Hulsbergen van de Kaa CA, Kaufmann D, Barentsz JO. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology 2004; 233(2): 449-456.
241. Harisinghani MG, Saksena M, Ross RW, Tabatabaei S, Dahl D, McDougal S, Weissleder R. A pilot study of lymphotrophic nanoparticle-enhanced magnetic resonance imaging technique in early stage testicular cancer: a new method for noninvasive lymph node evaluation. Urology 2005; 66(5): 1066-1071.
242. Tabatabaei S, Harisinghani M, McDougal WS. Regional lymph node staging using lymphotropic nanoparticle enhanced magnetic resonance imaging with ferumoxtran-10 in patients with penile cancer. J Urol 2005; 174(3): 923-927.
243. Nishimura H, Tanigawa N, Hiramatsu M, Tatsumi Y, Matsuki M, Narabayashi I. Preoperative esophageal cancer staging: magnetic resonance imaging of lymph node with ferumoxtran-10, an ultrasmall superparamagnetic iron oxide. J Am Coll Surg 2006; 202(4): 604-611.
244. Koh D-M, Brown G, Temple L, Raja A, Toomey P, Bett N, Norman AR, Husband JE. Rectal cancer: mesorectal lymph nodes at MR imaging with USPIO versus histopathologic findings - initial observations. Radiology 2004; 231(1): 91-99.
245. Rockall AG, Sohaib SA, Harisinghani MG, Babar SA, Singh N, Jeyarajah AR, Oram DH, Jacobs IJ, Shepherd JH, Reznek RH. Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J Clin Oncol 2005; 23(12): 2813-2821.
246. Shapiro EM, Medford-Davis LN, Fahmy TM, Dunbar CE, Koretsky AP. Antibody-mediated cell labeling of peripheral T cells with micron-sized iron oxide particles (MPIOs) allows single cell detection by MRI. Contrast Media Mol Imaging 2007; 2(3): 147-153.
247. Arbab AS, Bashaw LA, Miller BR, Jordan EK, Bulte JWM, Frank JA. Intracytoplasmic tagging of cells with ferumoxides and transfection agent for cellular magnetic resonance imaging after cell transplantation: methods and techniques. Transplantation 2003; 76(7): 1123-1130.
248. de Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, Boerman OC, Oyen WJ, Bonenkamp JJ, Boezeman JB, Adema GJ, Bulte JW, Scheenen TW, Punt CJ, Heerschap A, Figdor CG. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 2005; 23(11): 1407-1413.
249. Kobukai S, Baheza R, Cobb JG, Virostko J, Xie J, Gillman A, Koktysh D, Kerns D, Does M, Gore JC, Pham W. Magnetic nanoparticles for imaging dendritic cells. Magn Reson Med 2010; 63(5): 1383-1390.
250. Karagulle-Kendi AT, Truwit C. Neuroimaging of central nervous system infections. Handbook of Clinical Neurology Vol 96. Elsevier: Amsterdam, 2010; 239-255.
251. Krol S, Macrez R, Docagne F, Defer G, Laurent S, Rahman M, Hajipour MJ, Kehoe PG, Mahmoudi M. Therapeutic benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood brain barrier. Chem Rev 2012; 113(3): 1877-1903.
252. Petry K, Boiziau C, Dousset V, Brochet B. Magnetic resonance imaging of human brain macrophage infiltration. Neurotherapeutics 2007; 4(3): 434-442.
253. Dousset V, Brochet B, Deloire MSA, Lagoarde L, Barroso B, Caille J-M, Petry KG. MR imaging of relapsing multiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolinium. Am J Neuroradiol 2006; 27(5): 1000-1005.
254. Heyn C, Ronald JA, Mackenzie LT, MacDonald IC, Chambers AF, Rutt BK, Foster PJ. In vivo magnetic resonance imaging of single cells in mouse brain with optical validation. Magn Reson Med 2006; 55(1): 23-29.
255. Grossman RI, Braffman BH, Brorson JR, Goldberg HI, Silberberg DH, Gonzalez-Scarano F. Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. Radiology 1988; 169(1): 117-122.
256. Dousset V, Delalande C, Ballarino L, Quesson B, Seilhan D, Coussemacq M, Thiaudiere E, Brochet B, Canioni P, Caille JM. In vivo macrophage activity imaging in the central nervous system detected by magnetic resonance. Magn Reson Med 1999; 41(2): 329-333.
257. Dousset V, Gomez C, Petry K, Delalande C, Caille J-M. Dose and scanning delay using USPIO for central nervous system macrophage imaging. Magn Reson Mater Phys Biol Med 1999; 8(3): 185-189.
258. Kenzaoui BH, Bernasconi CC, Hofmann H, Juillerat-Jeanneret L. Evaluation of uptake and transport of ultrasmall superparamagnetic iron oxide nanoparticles by human brain-derived endothelial cells. Nanomedicine (Lond) 2012; 7(1): 39-53.
259. Dan M, Cochran DB, Yokel RA, Dziubla TD. Binding, transcytosis and biodistribution of anti-PECAM-1 iron oxide nanoparticles for brain-targeted delivery. PLoS One 2013; 8(11): e81051.
260. Floris S, Blezer ELA, Schreibelt G, Döpp E, van der Pol SMA, Schadee-Eestermans IL, Nicolay K, Dijkstra CD, de Vries HE. Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study. Brain 2004; 127(3): 616-627.
261. Dousset V, Ballarino L, Delalande C, Coussemacq M, Canioni P, Petry KG, Caillé J-M. Comparison of ultrasmall particles of iron oxide (USPIO)-enhanced T2-weighted, conventional T2-weighted, and gadolinium-enhanced T1-weighted MR images in rats with experimental autoimmune encephalomyelitis. Am J Neuroradiol 1999; 20(2): 223-227.
262. Rausch M, Hiestand P, Foster CA, Baumann DR, Cannet C, Rudin M. Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. J Magn Reson Imaging 2004; 20(1): 16-24.
263. Bendszus M, Stoll G. Caught in the act: in vivo mapping of macrophage infiltration in nerve injury by magnetic resonance imaging. J Neurosci 2003; 23(34): 10892-10896.
264. Arvin B, Neville LF, Barone FC, Feuerstein GZ. The role of inflammation and cytokines in brain injury. Neurosci Biobehav Rev 1996; 20(3): 445-452.
265. Zelivyanskaya ML, Nelson JA, Poluektova L, Uberti M, Mellon M, Gendelman HE, Boska MD. Tracking superparamagnetic iron oxide labeled monocytes in brain by high-field magnetic resonance imaging. J Neurosci Res 2003; 73(3): 284-295.
266. Rausch M, Hiestand P, Baumann D, Cannet C, Rudin M. MRI-based monitoring of inflammation and tissue damage in acute and chronic relapsing EAE. Magn Reson Med 2003; 50(2): 309-314.
267. Corot C, Petry KG, Trivedi R, Saleh A, Jonkmanns C, Le Bas J-F, Blezer E, Rausch M, Brochet B, Foster-Gareau P, Balériaux D, Gaillard S, Dousset V. Macrophage imaging in central nervous system and in carotid atherosclerotic plaque using ultrasmall superparamagnetic iron oxide in magnetic resonance imaging. Invest Radiol 2004; 39(10): 619-625.
268. Schilling M, Besselmann M, Leonhard C, Mueller M, Ringelstein EB, Kiefer R. Microglial activation precedes and predominates over macrophage infiltration in transient focal cerebral ischemia: a study in green fluorescent protein transgenic bone marrow chimeric mice. Exp Neurol 2003; 183(1): 25-33.
269. Saleh A, Schroeter M, Jonkmanns C, Hartung HP, Modder U, Jander S. In vivo MRI of brain inflammation in human ischaemic stroke. Brain 2004; 127(7): 1670-1677.
270. Deddens LH, Van Tilborg GA, Mulder WJ, De Vries HE, Dijkhuizen RM. Imaging neuroinflammation after stroke: current status of cellular and molecular MRI strategies. Cerebrovasc Dis 2012; 33(4): 392-402.
271. Oude Engberink RD, Blezer ELA, Hoff EI, van der Pol SMA, van der Toorn A, Dijkhuizen RM, de Vries HE. MRI of monocyte infiltration in an animal model of neuroinflammation using SPIO-labeled monocytes or free USPIO. J Cereb Blood Flow Metab 2007; 28(4): 841-851.
272. Henning EC, Ruetzler CA, Gaudinski MR, Hu TC, Latour LL, Hallenbeck JM, Warach S. Feridex preloading permits tracking of CNS-resident macrophages after transient middle cerebral artery occlusion. J Cereb Blood Flow Metab 2009; 29(7): 1229-1239.
273. Lorger M, Felding-Habermann B. Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis. Am J Pathol 2010; 176(6): 2958-2971.
274. Lorger M. Tumor microenvironment in the brain. Cancers 2012; 4(1): 218-243.
275. Enochs WS, Harsh G, Hochberg F, Weissleder R. Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent. J Magn Reson Imaging 1999; 9(2): 228-232.
276. Neuwelt EA, Varallyay P, Bago AG, Muldoon LL, Nesbit G, Nixon R. Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours. Neuropathol Appl Neurobiol 2004; 30(5): 456-471.
277. Zimmer C, Weissleder R, Poss K, Bogdanova A, Wright SC Jr, Enochs WS. MR imaging of phagocytosis in experimental gliomas. Radiology 1995; 197(2): 533-538.
278. Fleige G, Nolte C, Synowitz M, Seeberger F, Kettenmann H, Zimmer C. Magnetic labeling of activated microglia in experimental gliomas. Neoplasia 2001; 3(6): 489-499.
279. Sztriha LK, O'Gorman RL, Modo M, Barker GJ, Williams SCR, Kalra L. Monitoring brain repair in stroke using advanced magnetic resonance imaging. Stroke 2012; 43(11): 3124-3131.
280. Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Cayatte AJ, Mowery J. Atherosclerosis. Potential targets for stabilization and regression. Circulation 1992; 86(6 Suppl): III117-123.
281. Corot C, Petry KG, Trivedi R, Saleh A, Jonkmanns C, Le Bas JF, Blezer E, Rausch M, Brochet B, Foster-Gareau P, Baleriaux D, Gaillard S, Dousset V. Macrophage imaging in central nervous system and in carotid atherosclerotic plaque using ultrasmall superparamagnetic iron oxide in magnetic resonance imaging. Invest Radiol 2004; 39(10): 619-625.
282. Tang TY, Muller KH, Graves MJ, Li ZY, Walsh SR, Young V, Sadat U, Howarth SP, Gillard JH. Iron oxide particles for atheroma imaging. Arteriosclerosis Thromb Vasc Biol 2009; 29(7): 1001-1008.
283. Ruehm SG, Corot C, Vogt P, Kolb S, Debatin JF. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation 2001; 103(3): 415-422.
284. Schmitz SA, Coupland SE, Gust R, Winterhalter S, Wagner S, Kresse M, Semmler W, Wolf KJ. Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. Invest Radiol 2000; 35(8): 460-471.
285. Litovsky S, Madjid M, Zarrabi A, Casscells SW, Willerson JT, Naghavi M. Superparamagnetic iron oxide-based method for quantifying recruitment of monocytes to mouse atherosclerotic lesions in vivo: enhancement by tissue necrosis factor-alpha, interleukin-1beta, and interferon-gamma. Circulation 2003; 107(11): 1545-1549.
286. Lam T, Pouliot P, Avti PK, Lesage F, Kakkar AK. Superparamagnetic iron oxide based nanoprobes for imaging and theranostics. Adv Colloid Interface Sci 2013; 199-200: 95-113.
287. Hyafil F, Laissy JP, Mazighi M, Tchetche D, Louedec L, Adle-Biassette H, Chillon S, Henin D, Jacob MP, Letourneur D, Feldman LJ. Ferumoxtran-10-enhanced MRI of the hypercholesterolemic rabbit aorta: relationship between signal loss and macrophage infiltration. Arteriosclerosis Thromb Vasc Biol 2006; 26(1): 176-181.
288. Trivedi RA, JM UK-I, Graves MJ, Kirkpatrick PJ, Gillard JH. Noninvasive imaging of carotid plaque inflammation. Neurology 2004; 63(1): 187-188.
289. Schmitz SA, Taupitz M, Wagner S, Wolf KJ, Beyersdorff D, Hamm B. Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles. J Magn Reson Imaging 2001; 14(4): 355-361.
290. Trivedi RA, JM UK-I, Graves MJ, Cross JJ, Horsley J, Goddard MJ, Skepper JN, Quartey G, Warburton E, Joubert I, Wang L, Kirkpatrick PJ, Brown J, Gillard JH. In vivo detection of macrophages in human carotid atheroma: temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. Stroke 2004; 35(7): 1631-1635.
291. Zhang Z, Mascheri N, Dharmakumar R, Li D. Cellular magnetic resonance imaging: potential for use in assessing aspects of cardiovascular disease. Cytotherapy 2008; 10(6): 575-586.
292. Oude Engberink RD, van der Pol SM, Dopp EA, de Vries HE, Blezer EL. Comparison of SPIO and USPIO for in vitro labeling of human monocytes: MR detection and cell function. Radiology 2007; 243(2): 467-474.
293. Thorek DL, Tsourkas A. Size, charge and concentration dependent uptake of iron oxide particles by non-phagocytic cells. Biomaterials 2008; 29(26): 3583-3590.
294. Raynal I, Prigent P, Peyramaure S, Najid A, Rebuzzi C, Corot C. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10. Invest Radiol 2004; 39(1): 56-63.
295. Herborn CU, Vogt FM, Lauenstein TC, Dirsch O, Corot C, Robert P, Ruehm SG. Magnetic resonance imaging of experimental atherosclerotic plaque: comparison of two ultrasmall superparamagnetic particles of iron oxide. J Magn Reson Imaging 2006; 24(2): 388-393.
296. Tsuchiya K, Nitta N, Sonoda A, Otani H, Takahashi M, Murata K, Shiomi M, Tabata Y, Nohara S. Atherosclerotic imaging using 4 types of superparamagnetic iron oxides: new possibilities for mannan-coated particles. Eur J Radiol 2013; 82(11): 1919-1925.
297. Truijers M, Futterer JJ, Takahashi S, Heesakkers RA, Blankensteijn JD, Barentsz JO. In vivo imaging of the aneurysm wall with MRI and a macrophage-specific contrast agent. Am J Roentgenol 2009; 193(5): W437-441.
298. Richards JM, Shaw CA, Lang NN, Williams MC, Semple SI, MacGillivray TJ, Gray C, Crawford JH, Alam SR, Atkinson AP, Forrest EK, Bienek C, Mills NL, Burdess A, Dhaliwal K, Simpson AJ, Wallace WA, Hill AT, Roddie PH, McKillop G, Connolly TA, Feuerstein GZ, Barclay GR, Turner ML, Newby DE. In vivo mononuclear cell tracking using superparamagnetic particles of iron oxide: feasibility and safety in humans. Circ Cardiovasc Imaging 2012; 5(4): 509-517.
299. Nahrendorf M, Jaffer FA, Kelly KA, Sosnovik DE, Aikawa E, Libby P, Weissleder R. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 2006; 114(14): 1504-1511.
300. Chacko A-M, Hood ED, Zern BJ, Muzykantov VR. Targeted nanocarriers for imaging and therapy of vascular inflammation. Curr Opinion Colloid Interface Sci 2011; 16(3): 215-227.
301. McAteer MA, Sibson NR, von zur Muhlen C, Schneider JE, Lowe AS, Warrick N, Channon KM, Anthony DC, Choudhury RP. In vivo magnetic resonance imaging of acute brain inflammation using microparticles of iron oxide. Nat Med 2007; 13(10): 1253-1258.
302. Hoyte LC, Brooks KJ, Nagel S, Akhtar A, Chen R, Mardiguian S, McAteer MA, Anthony DC, Choudhury RP, Buchan AM. Molecular magnetic resonance imaging of acute vascular cell adhesion molecule-1 expression in a mouse model of cerebral ischemia. J Cereb Blood Flow Metab 2010; 30(6): 1178-1187.
303. Michalska M, Machtoub L, Manthey HD, Bauer E, Herold V, Krohne G, Lykowsky G, Hildenbrand M, Kampf T, Jakob P. Visualization of vascular inflammation in the atherosclerotic mouse by ultrasmall superparamagnetic iron oxide vascular cell adhesion molecule-1-specific nanoparticles. Arteriosclerosis Thromb Vasc Biol 2012; 32(10): 2350-2357.
304. Burtea C, Ballet S, Laurent S, Rousseaux O, Dencausse A, Gonzalez W, Port M, Corot C, Vander Elst L, Muller RN. Development of a magnetic resonance imaging protocol for the characterization of atherosclerotic plaque by using vascular cell adhesion molecule-1 and apoptosis-targeted ultrasmall superparamagnetic iron oxide derivatives. Arteriosclerosis Thromb Vasc Biol 2012; 32(6): e36-e48.
305. Lee SM, Lee SH, Kang HY, Baek SY, Kim SM, Shin MJ. Assessment of musculoskeletal infection in rats to determine usefulness of SPIO-enhanced MRI. Am J Roentgenol 2007; 189(3): 542-548.
306. Gellissen J, Axmann C, Prescher A, Bohndorf K, Lodemann KP. Extra- and intracellular accumulation of ultrasmall superparamagnetic iron oxides (USPIO) in experimentally induced abscesses of the peripheral soft tissues and their effects on magnetic resonance imaging. Magn Reson Imaging 1999; 17(4): 557-567.
307. Kaim AH, Jundt G, Wischer T, O'Reilly T, Frohlich J, von Schulthess GK, Allegrini PR. Functional-morphologic MR imaging with ultrasmall superparamagnetic particles of iron oxide in acute and chronic soft-tissue infection: study in rats. Radiology 2003; 227(1): 169-174.
308. Lee SM, Lee SH, Kang HY, Baek SY, Kim SM, Shin MJ. Assessment of musculoskeletal infection in rats to determine usefulness of SPIO-enhanced MRI. Am J Roentgenology 2007; 189(3): 542-548.
309. Baraki H, Zinne N, Wedekind D, Meier M, Bleich A, Glage S, Hedrich HJ, Kutschka I, Haverich A. Magnetic Resonance Imaging of Soft Tissue Infection with Iron Oxide Labeled Granulocytes in a Rat Model. PLoS ONE 2012; 7(12): e51770; doi: 10.1371/journal.pone.0051770
310. Hoerr V, Tuchscherr L, Huve J, Nippe N, Loser K, Glyvuk N, Tsytsyura Y, Holtkamp M, Sunderkotter C, Karst U, Klingauf J, Peters G, Loffler B, Faber C. Bacteria tracking by in vivo magnetic resonance imaging. BMC Biol 2013; 11: 63.
311. Bierry G, Jehl F, Holl N, Sibilia J, Froelich S, Froehlig P, Dietemann JL, Kremer S. Cellular magnetic resonance imaging for the differentiation of infectious and degenerative vertebral disorders: preliminary results. J Magn Reson Imaging 2009; 30(4): 901-906.
312. Ma Y, Pope RM. The role of macrophages in rheumatoid arthritis. Curr Pharm Des 2005; 11(5): 569-580.
313. Simon GH, von Vopelius-Feldt J, Fu Y, Schlegel J, Pinotek G, Wendland MF, Chen MH, Daldrup-Link HE. Ultrasmall supraparamagnetic iron oxide-enhanced magnetic resonance imaging of antigen-induced arthritis: a comparative study between SHU 555 C, ferumoxtran-10, and ferumoxytol. Invest Radiol 2006; 41(1): 45-51.
314. Weissleder R, Stark DD, Engelstad BL, Bacon BR, Compton CC, White DL, Jacobs P, Lewis J. Superparamagnetic iron oxide: pharmacokinetics and toxicity. Am J Roentgenol 1989; 152(1): 167-173.
315. Pouliquen D, Le Jeune JJ, Perdrisot R, Ermias A, Jallet P. Iron oxide nanoparticles for use as an MRI contrast agent: pharmacokinetics and metabolism. Magn Reson Imaging 1991; 9(3): 275-283.
316. Frank JA, Miller BR, Arbab AS, Zywicke HA, Jordan EK, Lewis BK, Bryant LH Jr, Bulte JW. Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents. Radiology 2003; 228(2): 480-487.
317. Arbab AS, Bashaw LA, Miller BR, Jordan EK, Lewis BK, Kalish H, Frank JA. Characterization of biophysical and metabolic properties of cells labeled with superparamagnetic iron oxide nanoparticles and transfection agent for cellular MR imaging. Radiology 2003; 229(3): 838-846.
318. Arbab AS, Yocum GT, Wilson LB, Parwana A, Jordan EK, Kalish H, Frank JA. Comparison of transfection agents in forming complexes with ferumoxides, cell labeling efficiency, and cellular viability. Mol Imaging 2004; 3(1): 24-32.
319. Arbab AS, Bashaw LA, Miller BR, Jordan EK, Bulte JW, Frank JA. Intracytoplasmic tagging of cells with ferumoxides and transfection agent for cellular magnetic resonance imaging after cell transplantation: methods and techniques. Transplantation 2003; 76(7): 1123-1130.
320. Bulte JW, Arbab AS, Douglas T, Frank JA. Preparation of magnetically labeled cells for cell tracking by magnetic resonance imaging. Methods Enzymol 2004; 386: 275-299.
321. Frank JA, Zywicke H, Jordan EK, Mitchell J, Lewis BK, Miller B, Bryant LH Jr, Bulte JW. Magnetic intracellular labeling of mammalian cells by combining (FDA-approved) superparamagnetic iron oxide MR contrast agents and commonly used transfection agents. Acad Radiol 2002; 9(2): S484-487.
322. Suzuki Y, Zhang S, Kundu P, Yeung AC, Robbins RC, Yang PC. In vitro comparison of the biological effects of three transfection methods for magnetically labeling mouse embryonic stem cells with ferumoxides. Magn Reson Med 2007; 57(6): 1173-1179.
323. Neri M, Maderna C, Cavazzin C, Deidda-Vigoriti V, Politi LS, Scotti G, Marzola P, Sbarbati A, Vescovi AL, Gritti A. Efficient in vitro labeling of human neural precursor cells with superparamagnetic iron oxide particles: relevance for in vivo cell tracking. Stem Cells 2008; 26(2): 505-516.
324. Montet-Abou K, Montet X, Weissleder R, Josephson L. Transfection agent induced nanoparticle cell loading. Mol Imaging 2005; 4(3): 165-171.
325. Reynolds F, Weissleder R, Josephson L. Protamine as an efficient membrane-translocating peptide. Bioconjugate Chem 2005; 16(5): 1240-1245.
326. Wu YJ, Muldoon LL, Varallyay C, Markwardt S, Jones RE, Neuwelt EA. In vivo leukocyte labeling with intravenous ferumoxides/protamine sulfate complex and in vitro characterization for cellular magnetic resonance imaging. Am J Physiol Cell Physiol 2007; 293(5): 26.
327. Arbab AS, Rad AM, Iskander AS, Jafari-Khouzani K, Brown SL, Churchman JL, Ding G, Jiang Q, Frank JA, Soltanian-Zadeh H, Peck DJ. Magnetically-labeled sensitized splenocytes to identify glioma by MRI: a preliminary study. Magn Reson Med 2007; 58(3): 519-526.
328. Arbab AS, Frank JA. Cellular MRI and its role in stem cell therapy. Regen Med 2008; 3(2): 199-215.
329. Arbab AS, Pandit SD, Anderson SA, Yocum GT, Bur M, Frenkel V, Khuu HM, Read EJ, Frank JA. Magnetic resonance imaging and confocal microscopy studies of magnetically labeled endothelial progenitor cells trafficking to sites of tumor angiogenesis. Stem Cells 2006; 24(3): 671-678.
330. Bluemke DA, Weber TM, Rubin D, de Lange EE, Semelka R, Redvanly RD, Chezmar J, Outwater E, Carlos R, Saini S, Holland GA, Mammone JF, Brown JJ, Milestone B, Javitt MC, Jacobs P. Hepatic MR imaging with ferumoxides: multicenter study of safety and effectiveness of direct injection protocol. Radiology 2003; 228(2): 457-464.
331. Harisinghani MG, Saini S, Weissleder R, Halpern EF, Schima W, Rubin DL, Stillman AE, Sica GT, Small WC, Hahn PF. Differentiation of liver hemangiomas from metastases and hepatocellular carcinoma at MR imaging enhanced with blood-pool contrast agent Code-7227. Radiology 1997; 202(3): 687-691.
332. Harisinghani MG, Saini S, Weissleder R, Hahn PF, Yantiss RK, Tempany C, Wood BJ, Mueller PR. MR lymphangiography using ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: radiographic-pathologic correlation. Am J Roentgenol 1999; 172(5): 1347-1351.
333. Mack MG, Balzer JO, Straub R, Eichler K, Vogl TJ. Superparamagnetic iron oxide-enhanced MR imaging of head and neck lymph nodes. Radiology 2002; 222(1): 239-244.
334. Fleige G, Seeberger F, Laux D, Kresse M, Taupitz M, Pilgrimm H, Zimmer C. In vitro characterization of two different ultrasmall iron oxide particles for magnetic resonance cell tracking. Invest Radiol 2002; 37(9): 482-488.
335. Bulte JW, Douglas T, Witwer B, Zhang SC, Strable E, Lewis BK, Zywicke H, Miller B, van Gelderen P, Moskowitz BM, Duncan ID, Frank JA. Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat Biotechnol 2001; 19(12): 1141-1147.
336. Frank JA, Miller BR, Arbab AS, Zywicke HA, Jordan EK, Lewis BK, Bryant LH, Bulte JWM. Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents. Radiology 2003; 228(2): 480-487.
337. Dodd CH, Hsu HC, Chu WJ, Yang P, Zhang HG, Mountz JD Jr, Zinn K, Forder J, Josephson L, Weissleder R, Mountz JM, Mountz JD. Normal T-cell response and in vivo magnetic resonance imaging of T cells loaded with HIV transactivator-peptide-derived superparamagnetic nanoparticles. J Immunol Methods 2001; 256(1/2): 89-105.
338. Ahrens ET, Feili-Hariri M, Xu H, Genove G, Morel PA. Receptor-mediated endocytosis of iron-oxide particles provides efficient labeling of dendritic cells for in vivo MR imaging. Magn Reson Med 2003; 49(6): 1006-1013.
339. Bulte JWM, Zhang S-C, van Gelderen P, Herynek V, Jordan EK, Duncan ID, Frank JA. Neurotransplantation of magnetically labeled oligodendrocyte progenitors: magnetic resonance tracking of cell migration and myelination. Proc Natl Acad Sci U S A 1999; 96(26): 15256-15261.
340. Mahmoudi M, Hosseinkhani H, Hosseinkhani M, Boutry S, Simchi A, Shane Journeay W, Subramani K, Laurent S. Magnetic resonance imaging tracking of stem cells in vivo using iron oxide nanoparticles as a tool for the advancement of clinical regenerative medicine. Chem Rev 2011; 111(2): 253-280.
341. Mizuno H, Tobita M, Uysal AC. Concise review: adipose-derived stem cells as a novel tool for future regenerative medicine. Stem Cells 2012; 30(5): 804-810.
342. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131(5): 861-872.
343. Caplan AI. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 2007; 213(2): 341-347.
344. Lewin JS, Nour SG, Duerk JL. Magnetic resonance image-guided biopsy and aspiration. Top Magn Reson Imaging 2000; 11(3): 173-183.
345. Jing X, Yang L, Duan X, Xie B, Chen W, Li Z, Tan H. In vivo MR imaging tracking of magnetic iron oxide nanoparticle labeled, engineered, autologous bone marrow mesenchymal stem cells following intra-articular injection. Joint Bone Spine 2008; 75(4): 432-438.
346. van Buul GM, Kotek G, Wielopolski PA, Farrell E, Bos PK, Weinans H, Grohnert AU, Jahr H, Verhaar JAN, Krestin GP, van Osch GJVM, Bernsen MR. Clinically translatable cell tracking and quantification by MRI in cartilage repair using superparamagnetic iron oxides. PLoS One 2011; 6(2): e17001; doi: 10.1371/journal.pone.0017001
347. Sharifi S, Bulstra SK, Grijpma DW, Kuijer R. Treatment of the degenerated intervertebral disc; closure, repair and regeneration of the annulus fibrosus. J Tissue Eng Regen Med 2014; doi: 10.1002/term.1866.
348. Jiang X, Chen J, Cai Z, Ya Z, Liu Z, Xie C, Wu Y, Wu P. In vivo tracking superparamagnetic iron oxide labeled adipose derived stem cells to repair rabbit degenerated intervertebral disc. J Clin Rehabil Tissue Eng Res 2011; 15(40): 7515-7519.
349. Lalande C, Miraux S, Derkaoui SM, Mornet S, Bareille R, Fricain JC, Franconi JM, Le Visage C, Letourneur D, Amédée J, Bouzier-Sore AK. Magnetic resonance imaging tracking of human adipose derived stromal cells within three-dimensional scaffolds for bone tissue engineering. Eur Cells Mater 2011; 21: 341-354.
350. Serpooshan V, Zhao M, Metzler SA, Wei K, Shah PB, Wang A, Mahmoudi M, Malkovskiy AV, Rajadas J, Butte MJ. The effect of bioengineered acellular collagen patch on cardiac remodeling and ventricular function post myocardial infarction. Biomaterials 2013; 34(36): 9048-9055.
351. Tallheden T, Nannmark U, Lorentzon M, Rakotonirainy O, Soussi B, Waagstein F, Jeppsson A, Sjögren-Jansson E, Lindahl A, Omerovic E. In vivo MR imaging of magnetically labeled human embryonic stem cells. Life Sci 2006; 79(10): 999-1006.
352. Au KW, Liao SY, Lee YK, Lai WH, Ng KM, Chan YC, Yip MC, Ho CY, Wu EX, Li RA, Siu CW, Tse HF. Effects of iron oxide nanoparticles on cardiac differentiation of embryonic stem cells. Biochem Biophys Res Commun 2009; 379(4): 898-903.
353. Carr CA, Stuckey DJ, Tatton L, Tyler DJ, Hale SJM, Sweeney D, Schneider JE, Martin-Rendon E, Radda GK, Harding SE, Watt SM, Clarke K. Bone marrow-derived stromal cells home to and remain in the infarcted rat heart but fail to improve function: an in vivo cine-MRI study. Am J Physiol Heart Circ Physiol 2008; 295(2): H533-H542.
354. Delo DM, Olson J, Baptista PM, D'Agostino RB Jr, Atala A, Zhu JM, Soker S. Non-invasive longitudinal tracking of human amniotic fluid stem cells in the mouse heart. Stem Cells Dev 2008; 17(6): 1185-1193.
355. Wang L, Deng J, Wang J, Xiang B, Yang T, Gruwel M, Kashour T, Tomanek B, Summer R, Freed D, Jassal DS, Dai G, Glogowski M, Deslauriers R, Arora RC, Tian G. Superparamagnetic iron oxide does not affect the viability and function of adipose-derived stem cells, and superparamagnetic iron oxide-enhanced magnetic resonance imaging identifies viable cells. Magn Reson Imaging 2009; 27(1): 108-119.
356. Vallée JP, Hauwel M, Lepetit-Coiffée M, Bei W, Montet-Abou K, Meda P, Gardier S, Zammaretti P, Kraehenbuehl TP, Herrmann F, Hubbell JA, Jaconi ME. Embryonic stem cell-based cardiopatches improve cardiac function in infarcted rats. Stem Cells Transl Med 2012; 1(3): 248-260.
357. + cells in a transgenic mouse model of ALS. In Vivo 2012; 26(1): 31-38.
358. Hu SL, Lu PG, Zhang LJ, Li F, Chen Z, Wu N, Meng H, Lin JK, Feng H. In vivo magnetic resonance imaging tracking of SPIO-labeled human umbilical cord mesenchymal stem cells. J Cell Biochem 2012; 113(3): 1005-1012.
359. Jackson JS, Golding JP, Chapon C, Jones WA, Bhakoo KK. Homing of stem cells to sites of inflammatory brain injury after intracerebral and intravenous administration: a longitudinal imaging study. Stem Cell Res Ther 2010; 1(2); doi: 10.1186/scrt17
360. Canzi L, Castellaneta V, Navone S, Nava S, Dossena M, Zucca I, Mennini T, Bigini P, Parati EA. Human skeletal muscle stem cell antiinflammatory activity ameliorates clinical outcome in amyotrophic lateral sclerosis models. Mol Med 2012; 18(1): 401-411.
361. Lu SS, Liu S, Zu QQ, Xu XQ, Yu J, Wang JW, Zhang Y, Shi HB. In vivo MR imaging of intraarterially delivered magnetically labeled mesenchymal stem cells in a canine stroke model. PLoS One 2013; 8(2): e54963; doi: 10.1371/journal.pone.0054963
362. Kallur T, Farr TD, Böhm-Sturm P, Kokaia Z, Hoehn M. Spatio-temporal dynamics, differentiation and viability of human neural stem cells after implantation into neonatal rat brain. Eur J Neurosci 2011; 34(3): 382-393.
363. Ladecola C, Alexander M. Cerebral ischemia and inflammation. Curr Opinion Neurol 2001; 14(1): 89-94.
364. Vezzani A. Inflammation and epilepsy. Epilepsy Curr 2005; 5(1): 1-6.